Spirea wins Innovate UK grant to advance next-generation ADC technology
Cambridge, UK, 17 June 2025: Spirea Limited, a biopharmaceutical company developing next-generation antibody drug conjugate (ADC) cancer therapeutics, is delighted to announce that the company has been awarded an Innovate UK Biomedical Catalyst Grant to further demonstrate the unique capabilities of its proprietary technology in next-generation ADCs. The 18-month Biomedical Catalyst project will commence in […]